Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the stock in a transaction on Friday, February 28th. The shares were bought at an average price of $4.76 per share, for a total transaction of $47,600.00. Following the acquisition, the chief executive officer now owns 2,361,730 shares of the company's stock, valued at approximately $11,241,834.80. The trade was a 0.43 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Mihael Hristos Polymeropoulos also recently made the following trade(s):
- On Tuesday, February 25th, Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock. The shares were bought at an average price of $4.46 per share, for a total transaction of $44,600.00.
Vanda Pharmaceuticals Price Performance
Shares of VNDA stock opened at $4.76 on Friday. The stock has a market cap of $277.58 million, a P/E ratio of -14.88 and a beta of 0.74. Vanda Pharmaceuticals Inc. has a one year low of $3.71 and a one year high of $6.75. The stock has a fifty day moving average price of $4.59 and a 200 day moving average price of $4.80.
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.06. The firm had revenue of $53.19 million during the quarter, compared to analysts' expectations of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. Equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Quantinno Capital Management LP bought a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at $48,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company's stock valued at $53,000 after acquiring an additional 4,374 shares during the period. XTX Topco Ltd bought a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at $69,000. Zacks Investment Management bought a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at $74,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at $84,000. 88.14% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several equities analysts have commented on VNDA shares. StockNews.com started coverage on Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a "hold" rating on the stock. HC Wainwright increased their price objective on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th.
Get Our Latest Research Report on Vanda Pharmaceuticals
Vanda Pharmaceuticals Company Profile
(
Get Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
